| pubmed-article:10441861 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10441861 | lifeskim:mentions | umls-concept:C0011882 | lld:lifeskim |
| pubmed-article:10441861 | lifeskim:mentions | umls-concept:C0001128 | lld:lifeskim |
| pubmed-article:10441861 | lifeskim:mentions | umls-concept:C0037494 | lld:lifeskim |
| pubmed-article:10441861 | lifeskim:mentions | umls-concept:C0041175 | lld:lifeskim |
| pubmed-article:10441861 | lifeskim:mentions | umls-concept:C0013125 | lld:lifeskim |
| pubmed-article:10441861 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:10441861 | pubmed:dateCreated | 1999-8-30 | lld:pubmed |
| pubmed-article:10441861 | pubmed:abstractText | A two-central randomised single-blind placebo-controlled study was conducted to assess efficacy of intravenous administration of trometamol salt of thioctic (alpha-lipoic) acid (Thioctacid 600, "ASTA Medica", Germany) in 200 ml of physiological solution in 40 non-insulin dependent diabetic patients with symptomatic diabetic neuropathy. 10 patients of the control group received a physiological solution stained with 1% solution of riboflavin mononucleate (B2 vitamin) as placebo. Intravenous infusion was administered once daily during a period of 3 weeks. Diabetic neuropathy score was assessed at the entry as well as on days 7, 14 and 21 of therapy. Indicators of lipid peroxidation (oxidative stress)--malonic dialdehyde levels in plasma and membranes of erythrocytes. Electroneuromyography were performed. Most of the patients (29) noted symptomatic improvement after 7-10 infusions and on day 14 a significant reduction of the diabetic neuropathy score was noted in comparison to a baseline (p < 0.05). The further improvement of clinical picture had been pronounced by day 21 (p < 0.001). Improvement of symptom score was obtained in 39 patients (97.5%). The response rate in the control group was 40%. Parameters of oxidative stress and electroneuromyography improved significantly in the main group of patients, while these in placebo group remained without changes. | lld:pubmed |
| pubmed-article:10441861 | pubmed:language | rus | lld:pubmed |
| pubmed-article:10441861 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10441861 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10441861 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10441861 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10441861 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10441861 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10441861 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10441861 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10441861 | pubmed:issn | 1997-7298 | lld:pubmed |
| pubmed-article:10441861 | pubmed:author | pubmed-author:IakhnoN NNN | lld:pubmed |
| pubmed-article:10441861 | pubmed:author | pubmed-author:KozlovaN ANA | lld:pubmed |
| pubmed-article:10441861 | pubmed:author | pubmed-author:Mozolevski?Iu... | lld:pubmed |
| pubmed-article:10441861 | pubmed:author | pubmed-author:StrokovI AIA | lld:pubmed |
| pubmed-article:10441861 | pubmed:author | pubmed-author:MiasoedovS... | lld:pubmed |
| pubmed-article:10441861 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10441861 | pubmed:volume | 99 | lld:pubmed |
| pubmed-article:10441861 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10441861 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10441861 | pubmed:pagination | 18-22 | lld:pubmed |
| pubmed-article:10441861 | pubmed:dateRevised | 2008-3-31 | lld:pubmed |
| pubmed-article:10441861 | pubmed:meshHeading | pubmed-meshheading:10441861... | lld:pubmed |
| pubmed-article:10441861 | pubmed:meshHeading | pubmed-meshheading:10441861... | lld:pubmed |
| pubmed-article:10441861 | pubmed:meshHeading | pubmed-meshheading:10441861... | lld:pubmed |
| pubmed-article:10441861 | pubmed:meshHeading | pubmed-meshheading:10441861... | lld:pubmed |
| pubmed-article:10441861 | pubmed:meshHeading | pubmed-meshheading:10441861... | lld:pubmed |
| pubmed-article:10441861 | pubmed:meshHeading | pubmed-meshheading:10441861... | lld:pubmed |
| pubmed-article:10441861 | pubmed:meshHeading | pubmed-meshheading:10441861... | lld:pubmed |
| pubmed-article:10441861 | pubmed:meshHeading | pubmed-meshheading:10441861... | lld:pubmed |
| pubmed-article:10441861 | pubmed:meshHeading | pubmed-meshheading:10441861... | lld:pubmed |
| pubmed-article:10441861 | pubmed:meshHeading | pubmed-meshheading:10441861... | lld:pubmed |
| pubmed-article:10441861 | pubmed:meshHeading | pubmed-meshheading:10441861... | lld:pubmed |
| pubmed-article:10441861 | pubmed:meshHeading | pubmed-meshheading:10441861... | lld:pubmed |
| pubmed-article:10441861 | pubmed:meshHeading | pubmed-meshheading:10441861... | lld:pubmed |
| pubmed-article:10441861 | pubmed:meshHeading | pubmed-meshheading:10441861... | lld:pubmed |
| pubmed-article:10441861 | pubmed:meshHeading | pubmed-meshheading:10441861... | lld:pubmed |
| pubmed-article:10441861 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10441861 | pubmed:articleTitle | [The efficacy of the intravenous administration of the trometamol salt of thioctic (alpha-lipoic) acid in diabetic neuropathy]. | lld:pubmed |
| pubmed-article:10441861 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10441861 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10441861 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:10441861 | pubmed:publicationType | English Abstract | lld:pubmed |
| pubmed-article:10441861 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
